Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Soleno Therapeutics, Inc.

Pfizer vs. Soleno: A Decade of R&D Investment

__timestampPfizer Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 201483930000002242216
Thursday, January 1, 201576900000004536244
Friday, January 1, 201678720000005184803
Sunday, January 1, 201776570000003068742
Monday, January 1, 201880060000007178000
Tuesday, January 1, 2019865000000016267000
Wednesday, January 1, 2020940500000023191000
Friday, January 1, 20211382900000021453000
Saturday, January 1, 20221142800000015265000
Sunday, January 1, 20231067900000025189000
Monday, January 1, 202410930000000
Loading chart...

Unveiling the hidden dimensions of data

Innovation in Pharmaceuticals: A Tale of Two Companies

In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Pfizer Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Pfizer consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2021 at approximately 14% higher than its 2014 levels. This commitment underscores Pfizer's strategy to maintain its leadership in the pharmaceutical industry.

Conversely, Soleno Therapeutics, a smaller player, has shown a more modest yet steadily increasing investment in R&D, with a notable 1,000% increase from 2014 to 2023. This growth reflects Soleno's ambition to carve out a niche in the market. The data highlights the diverse strategies of these companies, offering insights into their priorities and potential future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025